Thank you Hope Rugo!

Important message for treatm of ILC! #ESMOBreast24

All is said by Dr Rebecca Dent :

“Rapidly relapsing TNBC remains a critical research priority and clinical unmet need”.

Patients currently receive most treatment options in the (neo)adjuvant setting. We urgently need better treatment strategies

#ESMOBreast24 #ESMOAmbassadors

Warnings from FDA Tatiana Prowell, MD that we might focus too much on getting all pts to pCR = ‘target fascination’💣. The toxicity will be way too high for many pts. Thanks for highlighting this🙏 #bcsm #ESMOBreast24 OncoAlert

Great start #ESMOBreast24 with highly interesting talks on clinical trial design with stellar panel🤩 Sara Tolaney Tatiana Prowell, MD Stefan Michiels OncoAlert

Excelling symposium dedicated to lobular breast cancer! In beautiful city of Leuven. Dont miss it! Christine Desmedt Dr. Steffi Oesterreich ELBCC

Tomorrow my 🚂🚆leaves to #ESMOBreast24 . Looking forward to the exciting program

Terrific list. I’ve worked closely with John Haanen The Netherlands Cancer Institute & have found him to be a generous & thoughtful collaborator! He would be a terrific leader for Society for Immunotherapy of Cancer! Toni Choueiri, MD Myriam Chalabi Neeraj Agarwal, MD, FASCO MarleenKokLab Ben Tran Omid Hamid MD Sapna Patel

Indeed! And trials for TNBC should allow ER low pts! Highly likely that these pts will benefit from IO as well as suggested by KN756 and CM7FL #bcsm OncoAlert

Institutional visit by Ulrike Harjes senior editor Nature Medicine to The Netherlands Cancer Institute. Outstanding insightful lecture with take home mess that editors love to talk to scientists! Thanks for visiting us Ulrike!

🤩

Thanks JAMA for working with us on this important paper which provides a solid basis for prospective trials to optimize treatm for low stage TNBC with high TILs Barbara Pistilli Mafalda Oliveira The Netherlands Cancer Institute TILs Working Group #bcsm OncoAlert

Do u want to learn more on immunodiversity in cancer immunotherapy? Read this paper in Cancer Discovery by dreamteam from LUMC Leiden

Beautiful paper by Roberto Leon-Ferre and many others showing that pts with stage I TNBC and high TIL have an excellent survival even without chemotherapy. Happy to be part of it, many Dutch pts were included! Overtreatment is a huge problem for certain BC subgroups #bcsm OncoAlert

Important academic trial! Inspiration to do larger trial in non-pCR pts after chemo+pembro to see what value is of contin pembro vs capecitabine or combo

Many thanks Daniel Peeper for your vision, guidance and uniting NKI staff The Netherlands Cancer Institute🙏. Scientists like you make the NKI such a wonderful place. Together with Van Rheenen Lab it was such a wonderful experience to be the board of the RFC

I'm #hiring a #postdoc to join my research group at the NKI in Amsterdam. Are you interested in developing state-of-the-art genomics and proteomics technologies to study TCR : antigen interactions in cancer? Apply before the 8th of May: nki.nl/careers-study/…

#AcademicTwitter

Congrats Leila Akkari with very timely paper! We urgently need more info on how cancer cells shape the tumor microenvironment! The Netherlands Cancer Institute

Congrats Rik Lindeboom and team!

Couldnt agree more! We need trials to bring promising drugs to our pts! Especially in periods in which reimbursements can be slow 🇳🇱Thanks for your inspiring leadership Michiel van der Heijden! The Netherlands Cancer Institute